Skip to content
Austin Top 50
Author:
Adaptive Biotechnologies
Adaptive Biotechnologies Announces Plan to Separate Its MRD and Immune Medicine Businesses
June 15, 2026
Adaptive Biotechnologies Corporation Announces Proposed Convertible Senior Notes Offering
June 15, 2026
At ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ® MRD Testing Across Hematology Clinical Practice and Research
May 29, 2026
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
May 21, 2026
←
Previous Page
1
2